AAD 2025: Advancements in Dermatology

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis (AD) significantly reduced patients’ reliance on other topical treatments, oral corticosteroids, and biologics in both biologic-experienced (n = 125) and biologic-naive (n = 431) populations, suggesting this Janus kinase (JAK) inhibitor may serve as an effective steroid-sparing agent with potential for long-term disease management across different patient subgroups.

A panelist discusses how the comprehensive ADVANCES safety monitoring system data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) revealed distinct infection risk profiles between Janus kinase (JAK) inhibitors (upadacitinib/abrocitinib, n = 1686) and cytokine inhibitors (dupilumab/tralokinumab, n = 3352) in atopic dermatitis patients, with JAK inhibitors showing elevated relative risks for serious infections and Candida infections during the 180-day assessment period, potentially influencing treatment selection based on individual patient risk factors.

A panelist discusses how the evolving landscape of atopic dermatitis treatment is moving toward a more personalized approach that carefully balances efficacy goals with safety considerations, incorporating new targeted therapies alongside traditional options while also expressing excitement about emerging research in dermatology including novel bispecific antibodies, microbiome-based interventions, and noninvasive diagnostic technologies that may revolutionize disease management in the coming years.